To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue Sarcoma
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs TAEST 16001 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Osteosarcoma; Soft tissue sarcoma
- Focus Adverse reactions
- 20 Sep 2019 Planned primary completion date changed from 15 Jun 2019 to 15 Dec 2019.
- 13 Sep 2018 Status changed from not yet recruiting to recruiting.
- 13 Mar 2018 New trial record